Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
Frontiers in Oncology|October 26, 2020
Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional PhenotypeTakaomi Kessoku, Noritoshi Kobayashi, Masato Yoneda, et al.
Journal of Neurogastroenterology and Motility|April 9, 2026
Therapeutic Impact on Quality of Life in Adult Patients With Chronic Intestinal Pseudo-obstruction: A Multicenter, Cohort StudyKota Takahashi, Takaomi Kessoku, Hidenori Ohkubo, et al.
The Oncologist|June 28, 2021
Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food IntakeAnna Ozaki, Takaomi Kessoku, Yuki Kasai, et al.
Frontiers in Medicine|July 24, 2025
Patients with symptomatic uncomplicated diverticular disease have high fecal bile acid concentrationsTsumugi Jono, Yuki Kasai, Takaomi Kessoku, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|October 20, 2022
Comparison of long-term prognosis between non-obese and obese patients with non-alcoholic fatty liver diseaseMichihiro Iwaki, Takaomi Kessoku, Kosuke Tanaka, et al.
Trials|June 4, 2020
Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET studyAnna Ozaki, Takaomi Kessoku, Michihiro Iwaki, et al.
Journal of Neurogastroenterology and Motility|July 7, 2023
Natural History of Chronic Intestinal Pseudo-obstruction and Need for Palliative CareKosuke Tanaka, Hidenori Ohkubo, Atsushi Yamamoto, et al.
Alimentary Pharmacology & Therapeutics|July 21, 2020
The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiotaNoboru Misawa, Takuma Higurashi, Tomohiro Takatsu, et al.
International Journal of Molecular Sciences|August 7, 2021
The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic TargetTakaomi Kessoku, Takashi Kobayashi, Kosuke Tanaka, et al.
The Lancet. Gastroenterology & Hepatology|August 18, 2020
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trialTakaomi Kessoku, Kento Imajo, Takashi Kobayashi, et al.
Pageof 9